Evidence map›Paper›PMID 40000793›Full record

ArticleScientific reports2025

A nomogram to predict postoperative overall and cancer specific survival in patients with primary parotid squamous cell carcinoma: a population based study.

Xudong Liu, Jincai Xue, Fang Dong, Xingyue Wang, Youxin Tian, Qinjiang Liu, Jun Wang, Yunsheng Wang

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xudong Liu *Department of Head and Neck Surgery, Gansu Provincial Cancer Hospital, Lanzhou, 730000, China.
Jincai Xue *Department of Head and Neck Surgery, Gansu Provincial Cancer Hospital, Lanzhou, 730000, China.
Fang DongDepartment of Radiotherapy, Gansu Provincial Cancer Hospital, Lanzhou, 730000, China.
Xingyue WangDepartment of Head and Neck Surgery, Gansu Provincial Cancer Hospital, Lanzhou, 730000, China.
Youxin TianDepartment of Head and Neck Surgery, Gansu Provincial Cancer Hospital, Lanzhou, 730000, China.
Qinjiang LiuDepartment of Head and Neck Surgery, Gansu Provincial Cancer Hospital, Lanzhou, 730000, China.
Jun WangDepartment of Head and Neck Surgery, Gansu Provincial Cancer Hospital, Lanzhou, 730000, China.
Yunsheng WangDepartment of Head and Neck Surgery, Gansu Provincial Cancer Hospital, Lanzhou, 730000, China. 19519170048@163.com.

Funding

Gansu Province Health Industry Research Project GSWSKY2023-30Lanzhou Science and Technology Development Plan Project 2022-3-26
6 · The paper itself

Abstract

Primary parotid squamous cell carcinoma (pPSCC) is a rare salivary gland neoplasm. Due to the low incidence of pPSCC, there is a lack of clinical studies with large samples. The aim of this study was to identify prognostic factors and develop a nomogram for predicting overall survival (OS) and cancer specific survival (CSS) of pPSCC, with the goal of guiding clinical decision making. We identified eligible pPSCC patients from the Surveillance, Epidemiology, and End Results (SEER) database. All patients were randomly allocated to either the training or validation cohort in a 7:3 ratio. The X-tile software was utilized to determine the optimal cut-off values for age at diagnose, regional nodes examined, regional nodes positive, and tumor size, and changes continuous variables into categorical variables. Univariate and multivariate Cox regression analyses were used to identify independent prognostic factors. Based on the identified variables, two nomograms were developed and validated to predict the 1-, 3-, and 5-year OS and CSS of pPSCC. The accuracy of the prediction was evaluated using the C-index and calibration curve. Decision curve analysis (DCA) and receiver operating characteristic (ROC) were utilized to compare the nomogram with the American Joint Committee on Cancer (AJCC) stage system in order to assess its superiority. Furthermore, two risk stratification systems were established based on the constructed nomograms. From 2000 to 2019, a total of 2,187 pPSCC patients were screened from the SEER database. The incidence of pPSCC showed an overall upward trend, with the highest incidence in patients aged 71-80 years. The 495 patients with pPSCC ultimately identified from the SEER database were randomly allocated into a training cohort (n = 348) and a validation cohort (n = 147).Five independent prognostic variables were identified for OS, including age at diagnose, distant metastasis, AJCC stage, type of surgery, and tumor size. However, six independent prognostic variables were identified for CSS, with the addition of regional lymph node positivity as an additional variable. Nomograms of OS and CSS were established based on the results. In the training cohort and the validation cohort, the C-index of OS and CSS was 0.679, 0.677, 0.650 and 0.650 respectively. Calibration curve demonstrate that the predictions of 1-, 3-, and 5-year survival probability models for OS and CSS were generally consistent with actual observations in both the training cohort and the validation cohort. Our nomogram demonstrated a superior clinical net benefit compared to the AJCC 7th version, as indicated by DCA and ROC analysis. Additionally, patients were stratified into low-, middle-, and high-risk groups based on the nomogram risk score. The Kaplan-Meier curve demonstrated significant differences in survival among the three groups. In this study, new nomograms and risk classification systems were successfully developed to predict the 1-, 3-, and 5-year OS and CSS of pPSCC patients, which has good accuracy and superiority and can help doctors and patients make clinical decisions.

Indexed as

Carcinoma, Squamous CellNomogramsParotid NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasm StagingPrognosisROC CurveSEER ProgramCancer-specific survivalNomogramsOverall survivalParotid glandPrognostic factorsSquamous cell carcinoma

Identifiers

PMID40000793
PMCPMC11861303

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.